Uppsala 2nd October 2019
Nanexa receives “Notice of Allowance” for another patent application in the US.
Nanexa has received a so-called “Notice of Allowance” for another patent application in the US. A Notice of Allowance announces that the patent application is considered ready for approval. However, the process is still ongoing, and it is currently not possible to predict when a patent will be granted.
The company’s CEO David Westberg comments:
The patent application for which we have now received Notice of Allowance refers to PharmaShell® which is administered in every conceivable way, for example by parenteral injection, inhalation and by oral preparations. This means a considerable extension of our patent protection.
The patent that was approved at the beginning of the year is limited to PharmaShell® administered by injection, a strategy we chose to more easily push through our arguments and to shorten the path to an approved patent. In that process, we also filed by continuational patent application without that limitation and it is for the patent application that application we have now received Notice of Allowance.
I think it is extremely gratifying that we now have patent protection for all possible ways of administration for PharmaShell® and this of course strengthens us in our discussions with both current and future partners.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: email@example.com
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.